N Bradshaw
Overview
Explore the profile of N Bradshaw including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
239
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Edmondson R, OConnell R, Banerjee S, Mileshkin L, Sykes P, Beale P, et al.
Gynecol Oncol
. 2021 Oct;
163(3):524-530.
PMID: 34625284
Background: Aromatase inhibitors have been used empirically to treat a subset of patients with hormone receptor positive uterine leiomyosarcomas(LMS) and carcinosarcomas (UCS) mainly supported by retrospective data. We evaluated the...
2.
Banerjee S, Tang M, OConnell R, Sjoquist K, Clamp A, Millan D, et al.
Gynecol Oncol
. 2021 Aug;
163(1):72-78.
PMID: 34412908
Background: Hormonal therapies are commonly prescribed to patients with metastatic granulosa cell tumours (GCT), based on high response rates in small retrospective studies. Aromatase inhibitors (AIs) are reported to have...
3.
Friedlander M, Benson C, OConnell R, Reed N, Clamp A, Lord R, et al.
Gynecol Oncol
. 2021 Feb;
161(1):160-165.
PMID: 33608144
Background: Aromatase inhibitors are standard of care for low-grade endometrial stromal sarcomas (LGESS), based on very high response rates reported in retrospective studies. We evaluated the activity of anastrozole in...
4.
Saldanha J, Garrett R, Snaddon L, Longmuir M, Bradshaw N, Watt C, et al.
Scott Med J
. 2011 Nov;
56(4):203-5.
PMID: 22089040
The breast cancer risk of women already under family history surveillance was accurately assessed according to national guidelines in an attempt to rationalize the service. Women attending two breast units...
5.
Bradshaw N, Walker R
J Clin Pharm Ther
. 2009 Jan;
22(5-6):379-89.
PMID: 19160723
Objective: To examine the amount spent on cardiovascular drugs and coronary services in one health authority and to estimate the cost of translating recent trial evidence for HMG-CoA reductase inhibitors...
6.
Anderson E, Berg J, Black R, Bradshaw N, Campbell J, Carnaghan H, et al.
Br J Cancer
. 2008 Feb;
98(4):840-4.
PMID: 18283300
To evaluate current guidelines criteria for inclusion of women in special 'breast cancer family history' surveillance programmes, records were reviewed of women referred to Scottish breast cancer family clinics between...
7.
Bradshaw N, Holloway S, Penman I, Dunlop M, Porteous M
Gut
. 2003 Nov;
52(12):1748-51.
PMID: 14633955
Background: Individuals with first degree relatives affected with colorectal cancer (CRC) at a young age, or more than one relative affected but who do not fulfil the Amsterdam criteria for...
8.
SEGERS G, Bradshaw N, Archer D, Blissett K, Oliver R
Mol Plant Microbe Interact
. 2001 Mar;
14(3):367-77.
PMID: 11277434
Cladosporiumfulvum is a mitosporic ascomycete pathogen of tomato. A study of fungal genes expressed during carbon starvation in vitro identified several genes that were up regulated during growth in planta....
9.
Campbell H, Bradshaw N, Davidson R, Dean J, Goudie D, Holloway S, et al.
J Med Genet
. 2000 Sep;
37(9):684-91.
PMID: 10978360
Objective: To establish national clinical guidelines and integrated care pathways for five conditions (tuberous sclerosis (TS), Huntington's disease (HD), myotonic dystrophy (MD), neurofibromatosis type 1 (NF1), and Marfan syndrome (MS))...
10.
Bradshaw N, Brewer C, Fitzpatrick D, Murray G, Rodgers F, Porteous M, et al.
Eur J Hum Genet
. 1998 Nov;
6(5):445-58.
PMID: 9801869
In Scotland a national audit project has been undertaken to devise evidence-based guidelines for the clinical management of patients with tuberous sclerosis (TS), a dominantly inherited multisystem disorder. In order...